Prognostic factors for overall survival in castration-resistant metastatic prostate cancer treated with docetaxel (MeProCSS): results from a German real-world cohort
MeProCSS, consisting of routinely collected parameters prior to the start of chemotherapy, seems to effectively stratify patients with mCRPC into risk groups based on their metastatic burden, nutritional and inflammatory status. This model may guide treatment decisions and reveal a potentially often underestimated or overlooked urgency for additional measures as supportive palliative care in mCRPC patients. Further large and prospective studies are necessary for validation of MeProCSS-also in other systemic PC therapy regimens.
Authors
- Thomas Stefan Worst (ORCID: https://orcid.org/0000-0001-5429-126X)
- Svetlana Hetjens
- Maurice Stephan Michel (ORCID: https://orcid.org/0000-0001-7424-9085)
- Karl‐Friedrich Kowalewski (ORCID: https://orcid.org/0000-0003-2931-6247)
- Nadim Moharam (ORCID: https://orcid.org/0000-0001-5464-0626)
- Frederik Wessels (ORCID: https://orcid.org/0000-0003-4213-8692)
- F. Steffens
- Paul Patroi
- Katja Nitschke
- Manuel Neuberger (ORCID: https://orcid.org/0000-0003-4573-5134)
- Daniel Uysal
- Nicolas Carl
Institutions
- Heidelberg University (DE)
- University Hospital Heidelberg (DE)
- University Medical Centre Mannheim (DE)
Publication Details
- Journal
- International Urology and Nephrology
- Published
- 2025-01-27
- DOI
- https://doi.org/10.1007/s11255-025-04389-2
- Primary Topic
- Prostate Cancer Treatment and Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00